As we expand our pipeline to address unmet medical requirements in treating life-threatening attacks caused by Gram-unfavorable pathogens, we are pleased to possess partnered with Dr. Robert Hancock and The University of British Columbia to develop novel antibiotics which will augment our internal R&D initiatives in this area.june 30 ‘ The net loss allocable to common shareholders for the three months finished, 2010 was $2.1 million or per talk about compared to a net reduction allocable to common shareholders of $2.6 million or per share for the 90 days ended June 30, 2009. Cash used for operating actions through the quarter was around $1.1 million.5 million payment to reduce its outstanding debt balance.6 million in gross offering proceeds.m.Among patients going through hemodialysis , peginesatide administered once a month was as effectual as epoetin administered someone to three times a week in maintaining hemoglobin amounts. Rates of confirmed hemoglobin transfusions and excursions were similar in both groups. Adverse occasions in the EMERALD studies were very similar in the peginesatide and epoetin groupings and were in keeping with expected adverse events in patients undergoing hemodialysis. No between-group differences had been observed in the rate of events linked to the ESA class of medicines, including venous thromboembolic events, complications related to hemodialysis access, hypertension-related events, and cancer.